Lung Adenocarcinoma

Notably, synthetic PAMP administration recapitulates these anti-tumor effects, effectively reducing intracellular proline levels and impairing tumor progression in cellular and animal models. Together, our findings uncover a previously uncharacterized lncRNA-encoded micropeptide that orchestrates proline metabolic reprogramming to restrain LUAD development, offering new opportunities for metabolic intervention in precision oncology.

P=N/A, N=400, Recruiting, Sheba Medical Center

This first documented case demonstrates the therapeutic efficacy of crizotinib in ALK-IR rearranged NSCLC, emphasizing the importance of comprehensive molecular profiling in guiding precision oncology.

Our study identifies CHCHD3 as a mitochondrial protein upregulated in lung cancer that contributes to tumor cell proliferation and survival.

P1, N=36, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting | Trial completion date: Jan 2027 --> Oct 2028 | Initiation date: Aug 2025 --> Jun 2026 | Trial primary completion date: Jan 2027 --> Oct 2028

P4, N=110, Not yet recruiting, Centre Antoine Lacassagne

To sum up, DLGAP5 could contribute to proliferation and impede apoptosis of LUAD cells by activating autophagy activity, suggesting that targeting DLGAP5 might be a promising approach for LUAD treatment.

This case demonstrates that osimertinib can achieve an early, deep, and sustainable response in patients with a rare G719A/L861Q co-mutation. Prospective evidence is necessary for rare EGFR subtypes.

DS-8201 demonstrates potential as one of the effective salvage therapies following RC48 failure in HER2 altered solid tumors, showing significantly better disease control and a distinct, manageable toxicity profile. These findings highlight the importance of selecting personalized ADCs based on molecular subtypes and toxicity factors and provide a basis for future, larger-scale prospective studies.

P1, N=5, Not yet recruiting, University of Oklahoma

This case highlights how apparent treatment response can be misleading and may delay the recognition of an underlying malignancy. Reassessment should be considered when the clinical course becomes atypical or rapidly progressive, particularly in high-risk patients.

Reduced-dose dabrafenib and trametinib were initiated with prophylactic naproxen to mitigate the risk of pyrexia. Treatment has been continued for over 6 months with sustained disease stability. This case suggests that an upfront dose-attenuation strategy combined with proactive toxicity management, including pyrexia prophylaxis, may represent a practical approach to maintain treatment continuity and clinical benefit in selected very elderly or frail patients.